Catalyst Pharmaceuticals Inc.

11/13/2024 | Press release | Distributed by Public on 11/13/2024 16:45

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
MCENANY PATRICK J
2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [CPRX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
Chairman of Board of Directors
(Last) (First) (Middle)
355 ALHAMBRA CIRCLE, SUITE 801 		3. Date of Earliest Transaction (Month/Day/Year)
11/11/2024
(Street)
CORAL GABLES, FL 33134 		4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common stock, par value $0.001 per share 11/11/2024 M 230,000 A $4.01 4,708,169 D
Common stock, par value $0.001 per share 11/11/2024 S 230,000(1) D $23.548(2) 4,478,169 D
Common stock, par value $0.001 per share 11/12/2024 M 70,000 A $4.01 4,548,169 D
Common stock, par value $0.001 per share 11/12/2024 S 70,000(1) D $23.421(3) 4,478,169 D
Common stock, par value $0.001 per share 11/12/2024 M 192,000 A $3.54 4,670,169 D
Common stock, par value $0.001 per share 11/12/2024 S 192,000(1) D $23.201(4) 4,478,169 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase common stock $4.01 11/11/2024 M 230,000 (5) 01/02/2025 Common Stock 230,000 $ 0 2,362,745 D
Options to purchase common stock $4.01 11/12/2024 M 70,000 (5) 01/02/2025 Common Stock 70,000 $ 0 2,292,745 D
Options to purchase common stock $3.54 11/12/2024 M 192,000 (6) 05/29/2025 Common Stock 192,000 $ 0 2,100,745 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
MCENANY PATRICK J
355 ALHAMBRA CIRCLE, SUITE 801
CORAL GABLES, FL 33134 		X Chairman of Board of Directors

Signatures

/s/ Patrick J. McEnany 11/13/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
(2) Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.29 to $23.873 per share.
(3) Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.30 to $23.50 per share.
(4) Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.03 to $23.48 per share.
(5) Options vested in three equal tranches on January 2, 2019, 2020 and 2021.
(6) Options vested in three equal tranches on May 29, 2019, 2020 and 2021.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.